We deliver end-to-end support for inactivated vaccine drug substances within a robust pharmaceutical framework. Navigate our hierarchy via Pharmaceutical Development & Manufacturing → Drug Substance Development → Vaccine Development. Our teams convert complex whole-pathogen and toxoid concepts into manufacturable, well-characterized antigen preparations ready for downstream progression.
Overview of Inactivated Vaccine Development
Inactivated vaccines are built on intact but replication-incompetent organisms or toxins rendered nonfunctional while preserving protective epitopes. Successful development integrates cell substrate selection, seed system definition, upstream propagation design, inactivation kinetics, impurity clearance, adjuvant-ready formulation, and stability governance. We apply quality by design (QbD) to map critical quality attributes (CQAs)—identity, integrity, potency, safety-relevant residuals—and link them to critical process parameters (CPPs) through structured risk assessments and design of experiments (DoE).
Our Services
We provide an integrated suite spanning pharmaceutical development & manufacturing, drug substance development, and vaccine development—with emphasis on research and development activities that build process knowledge and assay readiness for confident advancement.
Cell Substrate and Seed System Development Service
We establish qualified cell substrates (e.g., mammalian, avian, or other accepted lines) and lineage-controlled master/working seeds. Activities include identity confirmation, growth kinetics profiling, adventitious agent panels, and small-scale productivity screens.
Upstream Propagation Process Development Service
We design scalable propagation strategies in batch, fed-batch, or perfusion formats. DoE matrices interrogate multiplicity of infection, residence time, temperature shifts, pH/DO set-points, nutrient feeds, and shear environment. Scale-down bioreactor models emulate larger vessels, enabling parameter ranges, control strategies, and robustness studies before engineering lots are contemplated.
Inactivation Strategy and Kinetics Development Service
We tailor inactivation approaches—chemical (e.g., beta-propiolactone, formaldehyde) or heat/hold regimens—to preserve key epitopes while ensuring replication cannot resume. Kinetic modeling, time-temperature/reagent maps, and orthogonal verification (infectivity assays, nucleic-acid signatures, structural readouts) anchor a compelling evidence package. Residual-reagent clearance plans are embedded early to streamline downstream processing.
Purification and Impurity Clearance Development Service
We configure clarification, filtration, and chromatography or density-based separations to enrich intact antigen and remove host cell DNA/protein, process reagents, aggregates, and adventitious by-products. Clearance claims are supported by mass balances, spike-recovery studies, and trending across scale-down models.
Analytical Method and Bioassay Development Service
We build and lifecycle-manage methods for identity (immunoassays, genomic signatures), integrity (particle sizing, electron microscopy access as applicable), potency (binding/neutralization surrogates), and safety-relevant residuals (host cell DNA/proteins, endotoxin, reagent remnants). Methods progress through feasibility and qualification with reference standards, system suitability, and matrix effect evaluations to support release, stability, and comparability.
Stability and Forced-Degradation Program Service
We design accelerated, stress, and long-term stability programs aligned to intended storage and distribution. Thermal, freeze–thaw, agitation, and light challenges map degradation pathways and guide formulation refinements. Hold-time and in-process stability studies support practical operations such as post-inactivation holds, filtration queues, and pool management without compromising quality.
We integrate proven platform capabilities, rigorous analytics, and a QbD framework to deliver high-quality inactivated vaccine drug substances. By focusing not only on technical execution but also on manufacturability, process robustness, and thorough characterization, we help reduce development risk and accelerate timelines. Partner with us to advance a scalable, well-understood antigen efficiently into later-stage development and clinical progression.
Our products and services are for research use only.
